Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (13635)	1/23/1998 1:22:00 AM
From: Andrew H	Read Replies (3) \| Respond to of 32384

>>What you and Henry have said makes sense. I wonder if LGND shareholders will avoid a knee-jerk reaction.<< Its an interesting question, Peter. I remember when they came out with some P2 results on Panretin and mentioned it looked good for a couple of indications and not so good for others--there was a brief and mild sell off after which it soon rebounded. Panretin is of course far more relevant to LGND's future than droloxifene (although if it were to become a billion dollar osteo drug, it could be significant at 3%). LGND has so many drugs in so many trials for so many indications that I find it hard to worry about something like this, especially when LGND has said the drug looks better for osteo. They will be getting their milestones in any case. I guess LGND could put out a release, but this seems so small in regard to their overall program, I suspect they will not comment.

To: Proton who wrote (13635)	1/23/1998 1:44:00 AM
From: Henry Niman	Respond to of 32384

P2, None of the wire services (Dow Jones, PRNewswire, Reuters) have linked the Droloxifene story to LGND.

To: Proton who wrote (13635)	1/24/1998 10:51:00 AM
From: RXGOLF	Read Replies (1) \| Respond to of 32384

Peter, What was your technical take on yesterday? As far as sentimental reaction, it appeared LGND was dealt with rather harshly yesterday. Possibly we are all a bit more timid after the DEPO debacle a short time ago. Did PFE feel that the FDA would not want another useful treatment for breast cancer? That is just a bit hard for me to understand when the shelves are full of NSAI's,ACE inhibitors,Beta blockers, etc. Anyway, I'm sure managed care would appreciate even a me too drug. That way they could work their now famous rebate(aka kick back program) to the lowest bidder! I am sure that a sucessful osteo drug would mean much more to the bottom line so I agree fully with your half-full take on Droloxifene. Maybe even 3/4 full? Enough rambling, thanks in advance for any technical summary you might be willing to share this weekend!! RXGOLF